Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inh...

    2026-01-28

    Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Tumor Angiogenesis Inhibition

    Executive Summary: Anlotinib hydrochloride (CAS 1058157-76-8) is a small-molecule multi-target tyrosine kinase inhibitor with nanomolar inhibitory activity against VEGFR2, PDGFRβ, and FGFR1, showing superior anti-angiogenic effects compared to sunitinib and sorafenib (Chen & Feng, 2019). It blocks VEGF/PDGF-BB/FGF-2-induced endothelial cell migration and capillary-like tube formation in vitro at concentrations as low as 5.6 nM. The compound demonstrates high oral bioavailability, tissue distribution to tumor and lung tissue, and a favorable safety profile in preclinical models. Anlotinib is supplied by APExBIO for research use and is not approved for diagnostic or therapeutic applications. Its action extends to modulation of the ERK signaling pathway, offering a benchmark tool for tumor angiogenesis inhibition studies (APExBIO product page).

    Biological Rationale

    Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is essential for tumor growth and metastasis (Chen & Feng, 2019). Tyrosine kinase receptors, particularly VEGFR2, PDGFRβ, and FGFR1, are critical mediators of angiogenic signaling in both physiological and pathological contexts. Inhibition of these receptors disrupts endothelial cell migration, proliferation, and capillary tube formation, directly limiting the supply of nutrients to tumor tissue. Multi-target TKIs like anlotinib enable the simultaneous blockade of several pro-angiogenic pathways, reducing compensatory signaling and resistance seen with single-target agents. The selectivity and potency of anlotinib make it a valuable tool for dissecting angiogenic processes and evaluating anti-angiogenic therapies in cancer research. Compared to older generation TKIs, anlotinib demonstrates improved selectivity and reduced off-target toxicity (Mechanistic overview).

    Mechanism of Action of Anlotinib (hydrochloride)

    Anlotinib hydrochloride is a small-molecule inhibitor that targets multiple receptor tyrosine kinases (RTKs) involved in angiogenesis and tumor progression. Its primary targets are:

    • VEGFR2 (vascular endothelial growth factor receptor 2) - IC50: 5.6 ± 1.2 nM
    • PDGFRβ (platelet-derived growth factor receptor beta) - IC50: 8.7 ± 3.4 nM
    • FGFR1 (fibroblast growth factor receptor 1) - IC50: 11.7 ± 4.1 nM

    Anlotinib also inhibits other RTKs, such as VEGFR1/3, FGFR2–4, PDGFRα, c-Kit, and Met, though with varying potency (Chen & Feng, 2019). The compound blocks ligand-induced phosphorylation of these receptors, preventing downstream activation of the ERK signaling pathway. This cascade inhibition leads to reduced endothelial cell migration, proliferation, and tube formation in angiogenesis assays. In preclinical models, anlotinib demonstrates superior efficacy and selectivity for angiogenic targets compared to sunitinib, sorafenib, and nintedanib (Mechanism & benchmarks). The compound’s action is dose-dependent and reversible upon withdrawal. Notably, anlotinib crosses the blood-brain barrier, accumulating in brain tissue in animal models.

    Evidence & Benchmarks

    • Anlotinib exhibits nanomolar potency in inhibiting VEGFR2 (IC50: 5.6 ± 1.2 nM), PDGFRβ (IC50: 8.7 ± 3.4 nM), and FGFR1 (IC50: 11.7 ± 4.1 nM) in biochemical assays (DOI:10.2147/OTT.S190333).
    • In cell-based assays using human vascular endothelial cells (EA.hy 926), anlotinib significantly inhibits VEGF/PDGF-BB/FGF-2-induced migration and tube formation in a concentration-dependent manner (DOI:10.2147/OTT.S190333).
    • Pharmacokinetics: Oral bioavailability ranges from 28% to 58% in rats and 41% to 77% in dogs; plasma protein binding is 93% in humans (APExBIO).
    • Tissue distribution studies reveal high accumulation in lung, liver, kidney, heart, and tumor tissue, with the ability to cross the blood-brain barrier (DOI:10.2147/OTT.S190333).
    • In a clinical case of intra-abdominal desmoplastic small round cell tumor (IADSRCT), anlotinib reduced metastatic lymph node size after four cycles, with manageable side effects (DOI:10.2147/OTT.S190333).
    • Compared to sunitinib, sorafenib, and nintedanib, anlotinib demonstrates superior inhibition of angiogenic processes and a higher therapeutic index (Mechanistic review).

    This article extends the mechanistic and benchmarking details previously summarized in Anlotinib Hydrochloride: Mechanisms, Benchmarks, and Research Integration by providing updated, granular pharmacokinetic and tissue distribution data for practical laboratory use.

    Applications, Limits & Misconceptions

    Anlotinib hydrochloride is primarily utilized in cancer research, especially in studies investigating tumor angiogenesis inhibition, endothelial cell migration, and signaling pathway modulation. It is suitable for:

    • Capillary-like tube formation assays in vitro.
    • Screening for inhibitors of VEGFR/PDGFR/FGFR signaling.
    • Assessment of anti-angiogenic drug candidates in animal models.
    • Mechanistic dissection of ERK and related pathways downstream of tyrosine kinase signaling.

    For more detailed guidance on assay design and reproducibility, see Optimizing Tumor Angiogenesis Assays with Anlotinib (hydrochloride), which addresses operational workflow and troubleshooting.

    Common Pitfalls or Misconceptions

    • Anlotinib is not approved for clinical or diagnostic use; it is intended strictly for research applications.
    • Its anti-angiogenic effects are context-dependent and may not fully recapitulate in vivo tumor microenvironment complexity.
    • Results observed in rodent models may not directly translate to human therapeutic outcomes.
    • Anlotinib is not selective for a single kinase; off-target effects can occur at higher concentrations.
    • Long-term exposure in vitro may induce adaptive resistance pathways not observed in short-term assays.

    Workflow Integration & Parameters

    Anlotinib hydrochloride (available as SKU C8688 from APExBIO) is supplied as a lyophilized powder and should be stored at -20°C. For typical in vitro angiogenesis or migration assays, recommended working concentrations range from 1 nM to 1 μM, with results most pronounced in the 5–100 nM range. The compound is soluble in DMSO and should be freshly diluted in buffer prior to cell treatment. In pharmacokinetic studies, oral administration in rodents yields peak plasma concentrations within 2–4 hours, and the drug is metabolized mainly via CYP3A to hydroxylated and dealkylated metabolites. High tissue distribution is observed in lung, liver, and tumor tissue, with minimal renal excretion of unchanged drug. Safety evaluations indicate a median lethal dose (LD50) of 1735.9 mg/kg in 14-day oral administration in rodent models, with no significant genotoxicity or organ toxicity detected. For troubleshooting and protocol details, see Optimizing Tumor Angiogenesis Assays with Anlotinib (hydrochloride), which provides scenario-based solutions beyond this mechanistic overview.

    Conclusion & Outlook

    Anlotinib hydrochloride represents a next-generation, multi-target TKI with superior potency and selectivity for VEGFR2, PDGFRβ, and FGFR1, enabling robust inhibition of tumor angiogenesis in research settings. Its validated use in cellular and animal models, favorable pharmacokinetics, and well-characterized safety profile position it as a benchmark compound for angiogenesis and kinase signaling studies. As new indications and resistance mechanisms are identified, careful assay design and context-specific interpretation remain critical. For comprehensive data sheets, ordering, and technical support, refer to the official Anlotinib (hydrochloride) product page by APExBIO.